News & Updates

What is a Pediatric Study Plan?

                        Our May CAC2 All-Member webinar focused on how pediatric cancer study plans are developed.  CAC2 Member Kelli Wright (CureSearch) introduced Dr. Brenda Weigel from University of Minnesota’s Masonic Cancer Center and Dr. Samuel Blackman of Day One Biopharmaceuticals [...]
Read more

Day One Biopharmaceuticals

Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in the market last week.  Its first agent, DAY101, licensed from Takeda Pharmaceuticals, is a targeted treatment for children with low grade glioma, a type of […]

Read more

Cancer in Children with Birth Defects: What Can We Learn from Population-Based Studies 

Our April CAC2 All-Member webinar hosted by Donna Ludwinski (Solving Kids Cancer) introduced Drs. Jeremy Schraw and Philip Lupo of Baylor College of Medicine who spoke about their research on nonchromosomal cancer predisposition.   Cancer in Children with Birth Defects: What Can We Learn from Population-Based Studies Studies show that birth defects […]

Read more

Joint Webinar Presentation: The Pandemic’s Impact on the Pediatric Cancer Research Landscape

Solving Kids’ Cancer and Max Cure Foundation offered a joint webinar: The Pandemic’s Impact on the Pediatric Cancer Research Landscape Timothy P. Cripe, Chief of Hematology and Oncology at Nationwide Children’s Hospital moderated the session that featured an all-star line-up: Peter Adamson, MD – former Chair, Children’s Oncology Group (COG) […]

Read more

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.